» Articles » PMID: 8194005

Pathologic Assessment of Tumor Regression After Preoperative Chemoradiotherapy of Esophageal Carcinoma. Clinicopathologic Correlations

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1994 Jun 1
PMID 8194005
Citations 772
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The benefits of preoperative chemotherapy and radiation for esophageal carcinoma are under investigation. A pilot study was undertaken to determine if pathologic assessment of tumor regression correlated with disease free survival.

Methods: Ninety-three resected specimens from patients treated with cis-dichloro-diamino cisplatin and irradiation before surgery were examined on semiserial sections. Patients selected for surgery were all Status 1 according to the World Health Organization (WHO) classification. Histologic typing was based on the WHO classification. Tumor regression grade (TRG) was quantitated in five grades: TRG 1 (complete regression) showed absence of residual cancer and fibrosis extending through the different layers of the esophageal wall; TRG 2 was characterized by the presence of rare residual cancer cells scattered through the fibrosis; TRG 3 was characterized by an increase in the number of residual cancer cells, but fibrosis still predominated; TRG 4 showed residual cancer outgrowing fibrosis; and TRG 5 was characterized by absence of regressive changes. Survival curves were estimated according to the Kaplan-Meier method. A quantification of the relationship between treatment failure and confounding variables (age, tumor location, tumor size, esophageal wall involvement by residual cancer and/or regressive changes, histology, treatment, adequacy of surgery, pathologic lymph node status, and tumor regression grade) was done using Cox's proportional hazards model.

Results: Forty-two percent of specimens were TGR 1-2; 20%, TGR 3; and 33%, TGR 4-5. Univariate analysis found that tumor size, pathologic lymph node status, tumor regression grade, and esophageal wall involvement were highly correlated with disease free survival (P < 0.05). After multivariate analysis, only tumor regression (i.e., TRG 1-3 versus TRG 4-5) remained a significant (P < 0.001) predictor of disease free survival.

Conclusions: This study highlights the importance of tumor regression in the survival of patients with esophageal carcinoma treated with preoperative chemoradiotherapy. These findings suggest that tumor regression grade should be considered when evaluating therapeutic results.

Citing Articles

Beyond the tumor region: Peritumoral radiomics enhances prognostic accuracy in locally advanced rectal cancer.

Liang Z, Yu M, Yang H, Li H, Xie H, Cui C World J Gastroenterol. 2025; 31(8):99036.

PMID: 40062323 PMC: 11886509. DOI: 10.3748/wjg.v31.i8.99036.


Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges.

Serra F, Valerio F, Pedrazzoli P, Vigano J, Caccialanza R, Cicognini D Drugs Context. 2025; 14.

PMID: 40017727 PMC: 11867168. DOI: 10.7573/dic.2024-10-7.


Combined tumor-associated microbiome and immune gene expression profiling predict response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer.

Roesel R, Strati F, Basso C, Epistolio S, Spina P, Djordjevic J Oncoimmunology. 2025; 14(1):2465015.

PMID: 39992705 PMC: 11853554. DOI: 10.1080/2162402X.2025.2465015.


Lymph node metastases status in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: a single-center cross-sectional study.

Nguyen A, Pham V, Tran M, Nguyen P Transl Gastroenterol Hepatol. 2025; 10:8.

PMID: 39944591 PMC: 11811556. DOI: 10.21037/tgh-24-76.


Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands.

van Laarhoven H, Verhoeven R, van Berge Henegouwen M, Haj Mohammad N, van Hillegersberg R, Slingerland M EClinicalMedicine. 2025; 80:103067.

PMID: 39911244 PMC: 11795631. DOI: 10.1016/j.eclinm.2024.103067.